[1] Germann UA. P-glycoprotein—a mediator of multidrug resistance in tumour cells [J]. Eur J Cancer, 1996, 32A (6): 927–44. [2] Krishna R, Mayer LD. Modulation of P-glycoprotein (PGP) mediated multidrug resistance (MDR) using chemosensitizers: recent advances in the design of selective MDR modulators [J]. Curr Med Chem Anticancer Agents, 2001, 1 (2): 163–174. [3] Tsuruo T, Iida H, Nojiri M, et al. Circumvention of vincristine and adriamycin resistance in vitro and in vivo by calcium influx blockers [J]. Cancer Res, 1983, 43 (6): 2905–2910. [4] Kiue A, Sano T, Naito A, et al. Enhancement of antitumour activity of etoposide by dihydropyridines on drug-sensitive and drug-resistant leukemia in mice [J]. Br J Cancer, 1991, 64 (2): 221–226. [5] Fisher GA, Sikic BI. Clinical studies with modulators of multi-drug resistance [J]. Hematol Oncol Clin North Am, 1995, 9 (2): 363–382. [6] Hyafil F, Vergely C, Vignaud PD, et al. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative [J]. Cancer Res, 1993, 53 (19): 4595–4602. [7] Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer [J]. Pharmacol Rev, 1990, 42 (3): 155–199. [8] Pennock GD, Dalton WS, Roeske WR, et al. Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration [J]. J Natl Cancer Inst, 1991, 83 (2): 105–110. [9] Sadzuka Y, Sugiyama I, Tsuruda T, et al. Characterization and cytotoxicity of mixed polyethyleneglycol modified liposomes containing doxorubicin [J]. Int J Pharm, 2006, 312 (1-2): 83–89. [10] Hobbs SK, Monsky WL, Yuan F, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment [J]. Proc Natl Acad Sci USA, 1998, 95 (8), 4607–4612. [11] Inaba M, Maruyama E. Reversal of resistance to vincristine in P388 leukemia by various polycyclic clinical drugs, with a special emphasis on quinacrine [J]. Cancer Res, 1988, 48 (8): 2064–2067. [12] Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters [J]. Nat Rev Cancer, 2002, 2 (1): 48–58. [13] Li X, Ruan GR, Lu WL, et al. A novel stealth liposomal topotecan with amlodipine: apoptotic effect is associated with deletion of intracellular Ca2+ by amlodipine thus leading to an enhanced anti-tumor activity in leukemia [J]. J Controlled Release, 2006, 112 (2): 186–198. [14] De Smet M, Van Belle SJ, Storme GA, et al. High-performance liquid chromatographic determination of vincaalkaloids in plasma and urine [J]. J Chromatogr B, 1985, 345 (2): 309–321. [15] Haran G, Cohen R, Bar LK, et al. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases [J]. Biochim Biophys Acta, 1993, 1151 (2): 201–215. [16] Abraham SA, Edwards K, Karlsson G, et al. An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes [J]. J Controlled Release, 2004, 96 (3): 449–461. [17] Vendrig DE, Holthuis JJ, Erdelyi-Toth V, et al. Solidphase extraction of vinblastine and vincristine from plasma and urine: variable drug recoveries due to non-reproducible column packings [J]. J Chromatogr B, 1987, 414 (1): 91–100. [18] Embree L, Gelmon KA, Tolcher AW, et al. Validation of a high-performance liquid chromatographic assay method for quantification of total vincristine sulfate in human plasma following administration of vincristine sulfate liposome injection [J]. J Pharm Biomed Anal, 1997, 16 (4): 675–687. [19] Cattel L, Ceruti M, Dosio F. From conventional to stealth liposomes: a new frontier in cancer chemotherapy [J]. Tumori, 2003, 89 (3): 237–249. [20] Rowinsky E, Donhower RC. Cancer chemotherapy and biotherapy [M]. Philadelphia: Lippincot-Raven Publishers, 1996. 263–275. [21] Scoazec JY, Krolak-Salmon P, Casez O, et al. Quinacrine induced cytolytic hepatitis in sporadic Creutzfeldt- Jakob disease [J]. Ann Neurol, 2003, 53 (4): 546–547. [22] Harrington KJ, Mohammadtaghi S, Uster PS, et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes [J]. Clin Cancer Res, 2001, 7 (2): 243–254. |